ArticlePsychoradiology2024
Identification of Parkinson's disease subtypes with distinct brain atrophy progression and its association with clinical progression.
Article in Psychoradiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 10 citations in OpenAlex.
- Local brain network alterations in prodromal and De Novo Parkinson's disease: basal ganglia functional connectivity mediates the association between regional homogeneity and motor manifestations.Behavioral and brain functions : BBF · 2026Article
- Multimodal brain network topology and enhanced computer-aided diagnosis in Parkinson's Disease: a systematic review and meta-analysis.NPJ digital medicine · 2026Article
- Data-driven subtyping of Parkinson's disease using MRI: current insights, challenges, and future directions.Frontiers in aging neuroscience · 2026Review
- Association between choroid plexus volume and cognitive function in older-age bipolar disorder.BMC psychiatry · 2025Article
- Synthetic MRI study of brain volume and subcortical myelin in various Parkinson's disease motor subtypes.NPJ Parkinson's disease · 2025Article
- Modifiable traits and genetic associations with grey matter volume in mid-to-late adulthood: a population-based study in the UK biobank.npj aging · 2025Article
- Progressive subcortical involvement as spinocerebellar ataxia type 3 advances.Orphanet journal of rare diseases · 2025Article
- Vitamin D-linked vulnerability and functional connectivity alterations in the superior frontal gyrus contributing to cognitive impairment in Parkinson's disease.Frontiers in aging neuroscience · 2025Article
- Neuroimaging-based data-driven subtypes of spatiotemporal atrophy due to Parkinson's disease.Brain communications · 2025Article
- PET, SPECT, and MRI imaging for evaluation of Parkinson's disease.American journal of nuclear medicine and molecular imaging · 2024Review
- Epidemiology of autonomic dysfunction in Parkinson's disease (Review).Medicine internationalReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Parkinson's disease (PD) patients suffer from progressive gray matter volume (GMV) loss, but whether distinct patterns of atrophy progression exist within PD are still unclear. Objective: This study aims to identify PD subtypes with different rates of GMV loss and assess their association with clinical progression. Methods: This study included 107 PD patients (mean age: 60.06 ± 9.98 years, 70.09% male) with baseline and ≥ 3-year follow-up structural MRI scans. A linear mixed-effects model was employed to assess the rates of regional GMV loss. Hierarchical cluster analysis was conducted to explore potential subtypes based on individual rates of GMV loss. Clinical score changes were then compared across these subtypes. Results: Two PD subtypes were identified based on brain atrophy rates. Subtype 1 (n = 63) showed moderate atrophy, notably in the prefrontal and lateral temporal lobes, while Subtype 2 (n = 44) had faster atrophy across the brain, particularly in the lateral temporal region. Furthermore, subtype 2 exhibited faster deterioration in non-motor (MDS-UPDRS-Part Ⅰ, Conclusion: The study has identified two PD subtypes with distinct patterns of atrophy progression and clinical progression, which may have implications for developing personalized treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.